Reported Saturday, Biomea Fusion Presents 52-Week COVALENT-111 Data Showing Durable Icovamenib Efficacy And 24% C-Peptide Index Increase In Type 2 Diabetes Subgroups

Benzinga Newsdesk www.benzinga.com Positive 95.2%

Neg 0% Neu 0% Pos 95.2%

Comments

No comments yet. Be the first!